Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/emm.2017.75 http://scihub22266oqcxt.onion/10.1038/emm.2017.75 C5519016!5519016 !28620220     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28620220 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28620220 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Exp+Mol+Med 2017 ; 49 (6 ): e345 Nephropedia Template TP {{tp|p=28620220 |t=2017. Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2 5 counteracts sepsis in rabbits |pdf=|usr=}}{{28620220 }} gab.com Text Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2 5 counteracts sepsis in rabbits JO: Exp Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=28620220 #FOAvip Sepsis, which is induced by severe bacterial infections, is a major cause of death worldwide, and therapies combating the disease are urgently needed. Because many drugs have failed in clinical trials despite their efficacy in mouse models, the development of reliable animal models of sepsis is in great demand. Several studies have suggested that rabbits reflect sepsis-related symptoms more accurately than mice. In this study, we evaluated a rabbit model of acute sepsis caused by the intravenous inoculation of Salmonella enterica. The model reproduces numerous symptoms characteristic of human sepsis including hyperlactatemia, hyperglycemia, leukopenia, hypothermia and the hyperproduction of several pro-inflammatory cytokines. Hence, it was chosen to investigate the proposed ability of Pep19-2.5-an anti-endotoxic peptide with high affinity to lipopolysaccharide and lipoprotein-to attenuate sepsis-associated pathologies in combination with an antibiotic (ceftriaxone). We demonstrate that a combination of Pep19-2.5 and ceftriaxone administered intravenously to the rabbits (1) kills bacteria and eliminates bacteremia 30?min post challenge; (2) inhibits Toll-like receptor 4 agonists in serum 90?min post challenge; (3) reduces serum levels of pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor ?); and (4) reverts to hypothermia and gives rise to temperature values indistinguishable from basal levels 330?min post challenge. The two components of the combination displayed synergism in some of these activities, and Pep19-2.5 notably counteracted the endotoxin-inducing potential of ceftriaxone. Thus, the combination therapy of Pep19-2.5 and ceftriaxone holds promise as a candidate for human sepsis therapy. Twit Text FOAVip Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2 5 counteracts sepsis in rabbits ????Exp Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=28620220 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28620220 #FOAvip English Wikipedia <ref>{{Cite pmid|28620220 }}</ref> Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2 5 counteracts sepsis in rabbits #MMPMID28620220 Bárcena-Varela S ; Martínez-de-Tejada G ; Martin L ; Schuerholz T ; Gil-Royo AG ; Fukuoka S ; Goldmann T ; Droemann D ; Correa W ; Gutsmann T ; Brandenburg K ; Heinbockel L Exp Mol Med 2017[Jun]; 49 (6 ): e345 PMID28620220 show ga Sepsis, which is induced by severe bacterial infections, is a major cause of death worldwide, and therapies combating the disease are urgently needed. Because many drugs have failed in clinical trials despite their efficacy in mouse models, the development of reliable animal models of sepsis is in great demand. Several studies have suggested that rabbits reflect sepsis-related symptoms more accurately than mice. In this study, we evaluated a rabbit model of acute sepsis caused by the intravenous inoculation of Salmonella enterica. The model reproduces numerous symptoms characteristic of human sepsis including hyperlactatemia, hyperglycemia, leukopenia, hypothermia and the hyperproduction of several pro-inflammatory cytokines. Hence, it was chosen to investigate the proposed ability of Pep19-2.5-an anti-endotoxic peptide with high affinity to lipopolysaccharide and lipoprotein-to attenuate sepsis-associated pathologies in combination with an antibiotic (ceftriaxone). We demonstrate that a combination of Pep19-2.5 and ceftriaxone administered intravenously to the rabbits (1) kills bacteria and eliminates bacteremia 30?min post challenge; (2) inhibits Toll-like receptor 4 agonists in serum 90?min post challenge; (3) reduces serum levels of pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor ?); and (4) reverts to hypothermia and gives rise to temperature values indistinguishable from basal levels 330?min post challenge. The two components of the combination displayed synergism in some of these activities, and Pep19-2.5 notably counteracted the endotoxin-inducing potential of ceftriaxone. Thus, the combination therapy of Pep19-2.5 and ceftriaxone holds promise as a candidate for human sepsis therapy. |Animals [MESH] |Anti-Bacterial Agents/administration & dosage/*therapeutic use [MESH] |Bacteremia/*drug therapy [MESH] |Ceftriaxone/administration & dosage/*therapeutic use [MESH] |Disease Models, Animal [MESH] |Drug Synergism [MESH] |Drug Therapy, Combination [MESH] |HEK293 Cells [MESH] |Humans [MESH] |Hyperlactatemia [MESH] |Hypothermia [MESH] |Interleukin-6/blood [MESH] |Leukopenia [MESH] |Lipopolysaccharides/blood [MESH] |Male [MESH] |Peptides/administration & dosage/*therapeutic use [MESH] |Rabbits [MESH] |Salmonella enterica/*drug effects [MESH] |Toll-Like Receptor 4/antagonists & inhibitors/blood [MESH]Coupling killing to neutralization: combined therapy with ceftriaxone/(epmc).pdf DeepDyve Pubget Overpricing